With a new patent settlement, Axsome Therapeutics can lower its sword against prospective generics makers taking aim at its narcolepsy med Sunosi. | The company inked another settlement with a prospective generic maker, leaving no further pending patent litigation for its Sunosi on the table.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Axsome has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040.
Takeda's first-in-class orexin treatment won an FDA nod in narcolepsy. Daiichi Sankyo faced investor pushback after admitting to…
Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to secure a…
Driven by personal losses, major unmet needs and a desire to diversify from the crowded oncology market, Fosun Pharma is making…
Scholar Rock has shed Novo Nordisk’s troubled Cata | Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a…
Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched
